Navigation Links
Novagali Pharma Completes a EUR15 Million Fund Raising
Date:9/26/2008

EVRY, France, September 26 /PRNewswire/ -- Novagali Pharma, a French Laboratory specialized in ophthalmology announces today it has secured EUR15 million in a new financing round with the participation of the historical Company investors.

Thanks to this new contribution Novagali Pharma will continue to develop its high potential projects:

- The commercialization in France and abroad of its first

marketable product, Cationorm(R), indicated for the treatment of dry eye

symptoms,

- The development of its flagship products: Vekacia(R) (Vernal

keratoconjunctivitis), Cyclokat(R) (Dry eye), Nova21027 (Glaucoma) and

Cortiject(R) (Diabetic macular edema), and particularly for Cyclokat(R)

the phase III clinical study now in course in Europe and the one

initiated in the United States during the third quarter of 2008 as well

as the phase I finalization in patient with Cortiject(R) started in

April 2008 in the United States.

Jerome Martinez, Novagali Pharma Chief Executive Officer, says: "The total amount of this fund rising strengthens once again our investors confidence to our development strategy, our products and our technological approach. This new source of financing will help us to carry on our company development".

About Novagali Pharma : http://www.novagali.com

Novagali Pharma is an ophthalmic pharmaceutical company that develops and commercializes innovative products. Thanks to its proprietary technology platforms Novasorb(R) and Eyeject(R), the company has developed a broad pipeline of 7 innovative products addressing main ocular conditions as well as orphan diseases. Most advanced products include Vekacia(R), an orphan product for treatment of vernal keratoconjunctivitis, Cyclokat(R), a product for the treatment of moderate-to-severe dry eye syndrome and Cortiject(R) for the treatment of diabetic retinopathies. Cat
'/>"/>

SOURCE Novagali Pharma SA
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Novagali Pharma Announces the Launch of Cationorm(R)
2. Memory Pharmaceuticals Completes Phase 1 Multiple Ascending Dose Study of R4996/MEM 63908
3. Napo Pharmaceuticals Will Provide Pediatric Formulation of Crofelemer at Cost to Developing Nations to Help Treat Life-Threatening Diarrhoel Diseases (Subject to FDA Approval)
4. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
5. Nuvelo and ARCA biopharma Announce Merger Agreement Creating Late-Stage Cardiovascular Biotechnology Company
6. New USP 797 Regulations May Create New Hazards for Compounding Pharmacy Directors
7. Helix BioPharma to Present L-DOS47 Research Findings at the National Research Council of Canadas Eighth Annual General Meeting of the Genomics and Health Initiative in Saskatoon, Canada
8. FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure From ARCA biopharma
9. AIT Laboratories Expands Pharma Services
10. Cyntellect Launches CellXpress(TM) System to Boost Productivity of Biopharmaceutical Process Development
11. EMEA Grants Kiadis Pharma Lead Product ATIR(TM) Orphan Drug Designation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... BURLINGAME, Calif. , July 24, 2014  ECC ... Denver, Colorado with University College Hospital ... of a development project to finance, design, construct, and ... Ibadan, Nigeria . Under the first ... and prepare scoping documents and funding applications. UCH Ibadan ...
(Date:7/24/2014)... team led by group leader Yung-Eun Sung has ... synthesize sulfur-doped and nitrogen-doped graphenes which can be ... and fuel cells. Yung-Eun Sung is both a ... at Institute for Basic Science* (IBS) and a ... achievement has great significance with regards to the ...
(Date:7/24/2014)... at the University of Delaware, is known worldwide ... engineering, environmental sustainability and electronics. , His early ... a well-defined, crystalline structure. At the atomic scale, ... zeolites can separate molecules with size differences of ... a nanometer), making them useful to the chemical ...
(Date:7/24/2014)... DUBLIN , July 24, 2014 ... the "Global Cell Culture Market 2014-2018" report ... Cell culture is the in vitro ... such as research, cell studies, and biopharmaceutical production. Cell ... vaccine production. Cell culture instruments and cell culture consumables ...
Breaking Biology Technology:ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2University of Delaware researcher describes new approach for creating organic zeolites 2Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 2
... Clinical Stage Product Portfolio -, ANN ... today announced that it is has completed ... commercialize products under AstraZeneca,s IP and,know-how regarding ... combination with,estrogen and progestin to treat endometriosis. ...
... IOMI ) today announced that Stanley C. Erck, ... the 10th Annual BIO,CEO & Investor Conference in New ... begin at 2 p.m. Eastern Time in the in ... give an update on corporate and clinical milestones and,detail ...
... Arena Pharmaceuticals, Inc.,(Nasdaq: ARNA ) announced today that ... & Investor Conference on February 12, 2008 at 9:30 ... Hotel in New York,City. David A. Walsey, Arena,s Director ... the company, including its clinical,development and discovery programs., ...
Cached Biology Technology:Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca 2Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca 3Iomai CEO to Speak at BIO CEO & Investor Forum on Feb. 12 2Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference 2Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference 3
(Date:7/25/2014)... engineering at the University of Houston, has written ... organ development., "Introduction to Tissue Engineering: Applications and ... the field of artificial organ development. Metin Akay, ... UH, served as a series editor on the ... published books on the subject of growing artificial ...
(Date:7/25/2014)... Spina bifda (SB) is a complex congenital central ... incomplete closing of the neural tubes during the ... spasticity, urinary and fecal incontinence and neurocognitive retardation. ... their quality of life. Researchers at Ankara Physical ... investigate the functional performance in children with SB, ...
(Date:7/25/2014)... The routine use of a molecular testing panel ... performing the correct initial surgery for patients with ... University of Pittsburgh Cancer Institute (UPCI), partner with ... Multidisciplinary Thyroid Center and other diagnostic testing agencies, ... initial surgery by 30 percent, according to the ...
Breaking Biology News(10 mins):University of Houston researcher publishes textbook on tissue engineering 2Test increases odds of correct surgery for thyroid cancer patients 2Test increases odds of correct surgery for thyroid cancer patients 3
... Rocky Mountains and Great Plains, have been decimated in ... spread by fleas. Plague outbreaks periodically sweep through ... virtually the entire population within months. Other prairie dogs ... is wiped out when the disease returns. This ...
... the sugar fructose, very common in the Western diet, to ... the cancer to grow more quickly, a study by researchers ... it,s widely known that cancers use glucose, a simple sugar, ... link has been shown between fructose and cancer proliferation, said ...
... Arizona ecologist plans to involve Tucson neighborhoods in a ... ecology designs ways for the natural world to exist ... biodiversity. "The threat to biodiversity is much, much, ... director of UA,s Tumamoc: People & Habitats and of ...
Cached Biology News:Carnivorous mice spread deadly plague in prairie dog towns, Stanford study finds 2Carnivorous mice spread deadly plague in prairie dog towns, Stanford study finds 3Carnivorous mice spread deadly plague in prairie dog towns, Stanford study finds 4Pancreatic cancers use fructose, common in the Western diet, to fuel their growth 2Pancreatic cancers use fructose, common in the Western diet, to fuel their growth 3Reconciliation ecology: The fun way to adapt to climate change 2Reconciliation ecology: The fun way to adapt to climate change 3
... number is a new product number, ... number. If showing no availability yet, ... number (Z71,487-9) or contact customer service ... neck 100 mm, No. of sidearm ...
... a metabolically stable analog of ... uterine stimulant and abortifacient which ... induce labor. It induces luteolysis ... when given as an intramuscular ...
TGase3 (S-20)...
Amodiaquine...
Biology Products: